dianabol steroids

Use of the drug dianabol steroids in women of reproductive age is only possible when using reliable methods of contraception, and if the patient is informed about the possible risk of treatment to the fetus.
Because cholesterol and substances synthesized from cholesterol are important for the development of the fetus, the potential risk of inhibition reductase inhibitors exceeds the benefit from the use of the drug during pregnancy. Contraindicated during pregnancy and lactation. In the case of diagnosis of pregnancy during therapy with reception ® should be discontinued immediately and the patient advised of the potential risk to the fetus.
If necessary, use during lactation, given the possibility of adverse events in infants, should decide the issue of termination of breastfeeding.

Dosing and Administration
The inside is not liquid and not crushing, swallowed whole with water, at any time of the day regardless of the meal.
Before starting therapy with  patient must begin to comply with the standard lipid-lowering diet and continue to observe her during treatment. The dose should be selected individually depending on indications and therapeutic response, taking into account the current conventional recommendation for target levels of lipids. If necessary, administration of the drug at a dose of 5 mg should be divided 10 mg tablet in two parts by risk.
The recommended initial dianabol steroids for patients who start taking the drug, or for patients transferred to other reception inhibitors reductase, is 5 or 1 to 10 mg once a day.When selecting the starting dose should be guided by the patient’s cholesterol and take into account the risk of developing cardiovascular complications, as well as the need to evaluate the potential risk of side effects. If necessary, after 4 weeks the dose can be increased.
Due to the possible development of adverse events when taking 40 mg dose compared to the lower doses of the drug (see., “Side effects” section) final titration to a maximum dose of 40 mg should only be carried out in patients with severe hypercholesterolemia and high risk of cardiovascular disease (particularly in patients with familial hypercholesterolemia) wherein when receiving a dose of 20 mg was reached target cholesterol levels, and which will be under medical supervision. patients with liver failure y patients with hepatic insufficiency with the values on the scale of Child-Pugh score below 7 dose adjustment is not required. patients with renal insufficiency In patients with renal insufficiency, mild dose adjustment is required. Recommended starting  per day.In patients with severe renal insufficiency (creatinine clearance less than 30 ml / min) use dianabol steroidscontraindicated. In patients with renal moderate impairment (creatinine clearance 30 – 60 ml / min) use  at a dose of 40 mg per day is contraindicated (see. section “Contraindications).

Specific populations. Elderly patients Patients 65 years and correction dose is not required. Patients with a predisposition to myopathy Application per day is contraindicated in patients with a predisposition to myopathy (cm. “Contra-section). At doses of 10 mg and 20 mg per day, the recommended initial dianabol steroids for this group of patients is 5 mg per day. Ethnic groups In the study of the pharmacokinetics of rosuvastatin parameters was observed increase in systemic concentrations of the drug in the representatives of the Mongoloid race (see. “Pharmacokinetics section). Keep in mind this fact when assigning  patients Mongoloid race. At doses of 10 and 20 mg of the recommended initial  for this group of patients is 5 mg per day. Application at a dose of 40 mg per day the representatives of the Mongoloid race is contraindicated (see. Section “Contraindications). In appointing with gemfibrozil dose should not exceed 10 mg per day.

Side effects
The incidence of adverse reactions was determined, respectively, following the graduation (the classification of the World Health Organization):

  • headache, dizziness, asthenic syndrome; very rarely – peripheral neuropathy, memory loss. From the digestive system: often – nausea, constipation, stomach pain; rarely – vomiting; rarely – pancreatitis; very rarely – hepatitis, jaundice; unspecified frequency – diarrhea. The respiratory system: rarely – cough, dyspnea. On the part of the endocrine system: often – type 2 diabetes. From the musculoskeletal system: often -mialgiya; very rarely – arthralgia; . rare – myopathy (including myositis), rhabdomyolysis Allergic reactions: rarely – itching, hives, rash; rarely – angioedema. Skin and subcutaneous tissue: unspecified frequency – Stevens-Johnson syndrome, peripheral edema. From the urinary system: often – proteinuria (with a frequency of more than 3% in patients receiving a dose of 40 mg), decreasing during therapy and not associated with the occurrence of kidney disease, urinary tract infection; . very rare – haematuria Laboratory indicators: rarely – transient dose-dependent increase in the activity of serum creatine phosphokinase, with an increase of more than 5 times in comparison with the upper limit of normal therapy should be temporarily suspended; . rare – transistor Thorne increased activity of aspartate aminotransferase and alanine aminotransferase As with other inhibitors, the incidence is dose-dependent side effects are usually expressed slightly and tested independently. In applying observed the following changes in laboratory parameters: increase in the concentration . glucose, bilirubin, alkaline phosphatase, gamma-glutamyl transferase When using other statins reported the following side effects:. depression, insomnia, decreased potency prolonged use of rosuvastatin reported isolated cases of interstitial lung disease.
  • Overdose
    In case of simultaneous reception of dianabol steroids multiple daily doses of rosuvastatin pharmacokinetic parameters are not changed. Treatment: specific treatment is not, being symptomatic therapy to maintain the functions of the vital organs and systems. Requires control of liver function. Hemodialysis is ineffective.